Amarin (AMRN) was the top gainer in June after recovering from profit taking in May. The company has shown continued progress in their pipeline, including completion of enrollment in the Phase III trial of Miraxion for Huntington’s disease. Endo Pharmaceuticals (ENDP) saw gains after announcing the launch of Synera anesthetic patch and approval of Opana (see page 4 & 5). Medivation (MDV), a company developing the neuroprotectant Dimebon for Alzheimer’s disease, gained ground after investors took speculative note of upcoming Phase II trial announcements…
